SuperworthBioCardia BCDA
- Market cap
- $13.9M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- −54.3%
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $357K+68% | $13K−88% | $55K−14% | $3K−93% | $0 | $0 | $0 | $0 | $0 | $0 | n/a | n/a | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| R&D | $1.9M−13% | $1.2M−48% | $1.2M−48% | $800K−65% | $931K−50% | $1.4M+22% | $1.5M+23% | $1.4M+71% | $936K+1% | $1.1M−20% | $1.2M−19% | $893K−35% |
| SG&A | $1.1M−4% | $941K+2% | $1.1M−9% | $852K−28% | $825K−24% | $906K−4% | $1.2M+10% | $683K−20% | $552K−33% | $885K−2% | $1M−14% | $730K+7% |
| −$2.6M−15% | −$2.1M−31% | −$2.3M−35% | −$1.6M−52% | −$1.8M−32% | −$2.3M+11% | −$2.7M+20% | −$2.1M+24% | −$1.5M−15% | −$2M−13% | −$2.3M−17% | −$1.6M−21% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$2.6M−16% | −$2.1M−32% | −$2.3M−35% | −$1.6M−52% | −$1.7M−33% | −$2.3M+11% | −$2.7M+20% | −$2M+25% | −$1.5M−15% | −$2M−14% | −$2.3M−17% | −$1.6M−21% |
| n/a | n/a | n/a | n/a | n/a | n/a | −$0.59 | −$0.40 | n/a | n/a | −$0.21−64% | n/a | |
| n/a | n/a | n/a | n/a | n/a | n/a | 4.6M | 5.1M | n/a | n/a | 10.8M+133% | n/a |
Gross profit: 22 periods, Q1 FY16 to Q4 FY21: not printed by the filing, worked out from its own lines.
EPS, diluted: 11 periods, Q4 FY10 to Q4 FY21: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY10 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY12 to Q4 FY15: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest BioCardia's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BCDABioCardia | $13.9M | n/m | 86.2× | n/m | n/m | n/m | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| Peer median | $64.6M | 13.6× | 14.8× | 1.1× | +6% | 4.9% |
More on BioCardia
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Shares outstanding
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .